What MobiDrop does

MobiDrop (Zhejiang) Co., Ltd. is a Hangzhou-headquartered life sciences instrumentation company, originally founded in Boston in 2018, that develops microfluidic single-cell sequencing and digital PCR platforms for academic research, clinical/precision-medicine, and pharmaceutical customers. The product architecture is built around patented barcoding and droplet-microfluidic IP and comprises four instruments — the MobiNova-100 single-cell system, the MobiNova-M1 microbial single-cell genome sequencer (Microbe-seq), the MobiNova-S1 high-throughput single-cell sorter, and the MobiGaea all-in-one droplet digital PCR system — supported by a consumable family of reagent kits (MobiCube 3' RNA-seq, MobiCube VDJ immune profiling, MobiChIP, MobiMicrobe) and bioinformatics software (MobiVision, MobiVision-M, MobiAnalyzer). The MobiVision stack automates transcriptomic, immune repertoire (TCR/BCR), and epigenomic analysis, with compatibility for downstream Illumina sequencing workflows validated through joint test data released in 2023.

Commercially, MobiDrop operates an enterprise field-sales motion combining direct sales to research institutions and pharma companies with regional distribution partners (notably Toyo Corporation for Japan) and service-provider resellers such as Rokit Genomics. Revenue is generated through a classic life-science tools structure: one-time instrument placement, recurring reagent/consumable pull-through, and software licensing, all on quote-based pricing. The company has been recognized by GEI as a potential unicorn in China's in-vitro diagnostics track and by Artery.com's 2023 Future Healthcare 100, and has established co-development alliances with Qingdao Single-cell Biotechnology, Shenzhen Salus Bio, Abiosciences, and Illumina. As of the input data, MobiDrop remains a private company with 11–50 employees, ~$13.3M raised in a 2022 Series A2 led by LYFE Capital, and operating geographies spanning China, the United States, Japan, and parts of Europe.

Name

MobiDrop

Legal name

MobiDrop (Zhejiang) Co., Ltd.

Website

https://mobidrop.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Short description

MobiDrop is a Hangzhou-based life sciences instrumentation company that develops microfluidic single-cell sequencing and digital PCR platforms, paired with reagent kits and bioinformatics software, serving academic research, precision medicine, and biopharma customers across China, Japan, the U.S., and Europe.

Ownership category

akta.pro rank

Product category

Life Sciences Research Instruments

NAICS

Analytical Laboratory Instrument Manufacturing (334516), In-Vitro Diagnostic Substance Manufacturing (325413), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical and Diagnostic Laboratories (6215)

SIC

Surgical & Medical Instruments & Apparatus (3841), In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)

akta.pro primary industry

Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays) (HLAGAIAF)

akta.pro secondary industries

Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays) (HLAAALAL), Laboratory Developed Tests (LDTs) & Specialized Clinical Lab Assays (HLAAALAN)

Keywords

• Single-cell sequencing
• Digital PCR
• Microfluidic instruments
• Genomics reagents
• Bioinformatics software

Headquarters

HQ city

Hangzhou

HQ country

China

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales

Revenue model

1. Instruments and Hardware: Sale of automated single-cell sequencing instruments (MobiNova-100, MobiNova-M1, MobiNova-S1) and digital PCR systems (MobiGaea). One-time hardware purchase model.
2. Reagents and Consumables: Recurring revenue from single-cell kits (MobiCube 3'RNA-seq, MobiCube VDJ, MobiChIP, MobiMicrobe) and digital PCR assays. Consumables repurchased with each run.
3. Software Licenses and Updates: MobiVision bioinformatics software for data analysis. Includes transcriptome, V(D)J, ChIP-seq, and ATAC-seq analysis pipelines.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

MobiDrop develops and manufactures dual microfluidic technology platforms — single-cell sequencing and droplet digital PCR — for life sciences research and precision medicine applications. The product portfolio comprises automated instruments (MobiNova-100, MobiNova-M1, MobiNova-S1, MobiGaea), recurring reagent kits (MobiCube, MobiChIP, MobiMicrobe), and bioinformatics analysis software (MobiVision, MobiAnalyzer), delivered to academic institutions, pharmaceutical companies, and clinical laboratories.

Product overview

MobiDrop is a life sciences technology company offering a comprehensive dual technology platform for single-cell sequencing and digital PCR. The product portfolio consists of instruments (MobiNova-100, MobiNova-M1, MobiNova-S1),配套试剂盒 (MobiCube® 3'RNA-seq, MobiCube® Immune Profiling, MobiChIP™, MobiMicrobe®), and bioinformatics software (MobiVision, MobiVision-M). The MobiNova instruments utilize proprietary microfluidic and barcoding technologies for single-cell capture and partitioning, while the MobiVision software suite provides automated analysis pipelines for transcriptomics, V(D)J immune repertoire, and epigenomics. The MobiGaea® Digital PCR system rounds out the offering for absolute nucleic acid quantification.

Differentiator

Problem solved

Functional benefit

Brands

• MobiNova-100: Single Cell System utilizing patented barcoding and microfluidic technologies for single cell partitioning and cell capture
• MobiNova-M1
• MobiGaea
• MobiCube
• MobiMicrobe
• MobiChIP
• MobiVision
• MobiVision-M
• MobiSort
• MobiAnalyzer

Products and services

• MobiNova-100 Single Cell System High-throughput single-cell multiomics instrument utilizing patented barcoding and microfluidic technologies for reliable single cell partitioning and effective cell capture, profiling tens of thousands of cells in a single run. Used by life sciences research institutions.
• MobiNova-M1 Microbial Single-Cell Genome Sequencing System

Quantifiable outcome

• Profile tens of thousands of cells in a single run
• +1 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature6 records

Partnerships

Five partnerships are on record, tiered key, core and minor.

• Toyo CorporationkeyChannel Partner/ Reseller/ Distributor · 4 March 2025MobiDrop CEO Pei Hao visited Tokyo, Japan to strengthen strategic partnerships with Toyo Corporation and explore cutting-edge single-cell collaboration opportunities. Toyo Corporation serves as a regional distribution partner for MobiDrop products in Japan.
• IlluminakeyTechnology or Integration · 28 June 2023Joint test data released between MobiDrop and Illumina, representing deepening cooperation. MobiDrop platforms utilize Illumina sequencing technology for downstream analysis.
• Shenzhen Salus Bio Medical Technology Co., Ltd.keyStrategic or Co-development Partner · 12 March 2023Strategic cooperation enabling MobiNova platform compatibility with Salus Pro, a domestic high-throughput sequencing platform. The partnership aims to jointly build a new molecular diagnostic and life science research platform with higher throughput, higher efficiency, more flexibility, and lower cost.
• Qingdao Single-cell Biotechnology Co., Ltd.coreStrategic or Co-development Partner · 17 February 2023Strategic cooperation to jointly innovate, develop and promote products and applications based on single-cell technology. The partnership combines Single-cell Biotech's Ramanome analysis and single-cell Raman sorting capabilities with MobiDrop's MobiMicrobe high-throughput genome and transcriptome sequencing to establish 'metabolic function-targeted high-throughput single-cell multi-omics' instrumentation systems.
• Rokit GenomicsminorChannel Partner/ Reseller/ DistributorService provider partner offering single-cell sequencing services using MobiDrop platforms. Rokit Genomics was awarded Top single cell sequencing service in APAC 2025 by Life Sciences Review.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Stilla Technologies: Provides the Naica digital PCR system using droplet microfluidic technology for absolute nucleic acid quantification. Directly competes with MobiDrop's MobiGaea system, with comparable throughput and sensitivity claims.
• 10x Genomics: The dominant single-cell sequencing platform vendor with Chromium, leveraging droplet-based microfluidics for partitioning and barcoding. Directly competes with MobiNova in academic and translational research workflows, but with a far larger installed base and broader assay menu.
• Takara Bio: Offers SMART-Seq single-cell RNA-seq kits and ICELL8 single-cell systems, overlapping with MobiDrop's reagent-kit and single-cell multiomics workflows. Especially comparable in academic and translational single-cell transcriptomics.
• Standard BioTools (formerly Fluidigm): Pioneer in microfluidic-based single-cell genomics (C1, Hyperion imaging mass cytometry) and now in mass cytometry and microfluidics. Directly comparable on microfluidic technology lineage, though with broader translational and clinical exposure.
• Bio-Rad Laboratories: Sells ddSEQ single-cell sequencing solutions and the QX200/QXDx droplet digital PCR platform, directly overlapping MobiDrop's dual technology positioning in both single-cell (ddSEQ) and digital PCR (QXDx) markets.
• Mission Bio: Specializes in single-cell multi-omics for oncology, including DNA + protein co-detection using droplet microfluidics. Comparable to MobiDrop's translational and clinical research positioning, especially for clonal hematopoiesis and tumor heterogeneity studies.
• Parse Biosciences: Provides Evercode single-cell RNA-seq kits using a combinatorial barcoding approach without dedicated instruments. Directly comparable to MobiDrop's reagent kits for fixed-cell and scalable single-cell profiling, particularly in early-stage academic accounts.
• BD Biosciences: Sells BD Rhapsody single-cell analysis systems using a microwell-based approach. A direct competitor to MobiNova in single-cell multiomics, backed by a much larger parent (Becton Dickinson) with deep clinical sales reach.

Broad incumbents

• Illumina: Dominant next-generation sequencing platform vendor and a strategic technology partner to MobiDrop. While not a direct head-to-head competitor in front-end sample prep, Illumina's roadmap decisions shape MobiDrop's downstream sequencing economics and strategic optionality.
• Roche (Digital PCR / Life Science): Through Digital LightCycler and Kapa reagents, Roche is a broad life-science tools incumbent with growing presence in digital PCR. Comparable to MobiGaea at the high-throughput digital PCR tier, with deeper clinical/commercial reach.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights8 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds3 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MobiDrop